Although HER2-DC1 s.c. combined with anti-HER2 antibodies treatment reduced tumor burden and improved survival, it was not able to prolong infiltration of immune cells into the tumor and completely arrest tumor growth in a HER2pos BC model. This evidence concerns the gene ERBB2 and breast cancer.